This informative book provides a wealth of information on ovarian cancer. The book opens with a discussion of contemporary management of this disease with commentary on surgery and clinical trials: neoadjuvant, dose-dense, and heated intraperitoneal chemotherapy (HIPEC}, as well as immunotherapy, vaccine therapy, emerging therapies. This is followed by presentations on ovarian cancer pathology. A chapter is devoted to methods of drug discovery through a functional genomics approach, with gene expression microarray databases available in public data repositories such as Public Gene Expression Omnibus (GEO} and validation using immunohistochemistry or Ingenuity Pathway Analysis (IPA). Next, the book explores the psycho-social issues that may be encountered by an ovarian cancer patient, including commentary on pain, fertility, anxiety, depression, demoralization, caregiver burnout, and end-of-life. The final chapter represents a step out from mainstream medical practice and provides an exposition of the mind-body interaction and the powerful role of belief in the healing process, with discussions of the placebo effect, nocebo effect, and numerous research studies that demonstrate the tremendous influence of our beliefs on our bodies and well-being. <p></p> Key Features: - Provides a holistic view of ovarian cancer - Covers both conventional medical research topics and key social issues encountered by patients, caregivers and medical professionals. - Explains cancer pathology and related concepts with the help of illustrations and notes on future directions - Features commentary from experts in ovarian cancer treatment - Written in a reader-friendly style suitable for a wide range of readers <p></p> Ovarian Cancer – Challenges and Innovations is a comprehensive reference about ovarian cancer for medical students, residents, practitioners, healthcare support staff (nurses, physician assistants), medical researchers and scientists, as well as patients and interested laypersons seeking to improve their current knowledge of ovarian cancer

The number of new discoveries related to diagnostics and therapeutics of hematological cancer is significant. These have resulted in continuous progress in fundamental knowledge about molecular and cellular mechanisms in hematological neoplasia. Physiopathogenesis of Hematological Cancer presents a concise overview of the cellular and molecular biology of myelo- and Lymphoproliferative disorders. The expert reviews presented within this e-book are also accompanied by bibliographic references for relevant scientific literature. This book should prove to be a valuable reference tool for both medical graduate and postgraduates in the field of oncology.

The book presents recent advances in the field of angiogenesis and antiangiogenesis. Starting with the hypothesis of Judah Folkman that tumor growth is angiogenesis dependent, this area of research now has a solid scientific foundation. Tumor growth, metastasis, progression, dormancy and apoptosis depend on angiogenesis: several clinical studies have shown a positive correlation between the number of vessels in the tumor, metastasis formation and disease prognosis. A number of approaches have been developed to inhibit tumor angiogenesis, and numerous compounds discovered that inhibit angiogenesis, but only a few of them proved effective in vivo and only a couple of agents were able to induce tumor regression. These and other related developments described in the book should prove to be of interest to a large number of readers wishing to keep abreast with the latest developments in the field.

Tumor development and progression are multi-factorial processes, in which genomic alterations and modifications in gene expression in pre-malignant cells are joined by deleterious microenvironmental factors. The tumor microenvironment contains stroma cells and leukocytes, soluble factors and matrix components. The intensive interplay that exists between the host factors and the tumor cells plays a major role in dictating the final outcome of the malignant process. Inflammatory mediators are pivotal microenvironmental factors present in the tumor milieu. These inflammatory components support cell growth and invasion, induce mutagenesis, increase angiogenicity, and suppress potential anti-tumor immune functions. The inflammatory constituents that prevail in tumors include leukocytes and soluble mediators - cytokines and chemokines. This e-book describes the roles played by these mediators in malignancy, and explains the basis for their consideration as therapeutic targets in cancer. The e-book is a timely overview of the roles played by inflammatory soluble mediators in neoplastic diseases. The topics addressed in this volume serve as a handy reference to investigators studying basic aspects of the malignant tumor growth, to clinicians who wish to better understand the processes involved in malignancy, and to pharmacological professionals seeking novel candidates for therapeutic intervention in cancer.

This e-book explains the essential role of angiogenesis in the progression and spread of the neoplasm, including the mechanics of initial carcinogenesis in promoting malignant transformation. The e-book deals with specific categories or subtypes of tumors with some emphasis on astrocytomas and glioblastoma multiforme. The process of carcinogenesis has been re-interpreted in terms of deranged physiologic principles and hence reference is made to what upsets homeostatic mechanisms. Readers of this e-book will have an opportunity to appreciate the essential role of angiogenesis not only in progression and spread of the neoplasm but especially also in the mechanics of initial carcinogenesis in promoting malignant transformation. This e-book should be a useful reference for scholars and clinicians interested in learning about cancer pathophysiology.

Cancer is a disease responsible for several million annual deaths among humans, worldwide. However, advances in healthcare - which include breakthroughs in science and medicine as well as access to medical treatment - have improved the survival rate of cancer patients over the last few decades.

Therapeutic Revolution relates the story of one of the great scientific tales of the twentieth century: how the field of medical oncology was created and its subsequent development owing to medical and scientific breakthroughs. The book unfolds the pre-clinical and clinical concepts and innovations that led to the creation of the medical subspecialty now known as oncology.

Therapeutic Revolution is the first book ever written on the events that led to this subspecialty of internal medicine. It relates the recollection of key events obtained from interviews of the pioneers who laid the foundations of medical oncology, as well as the author’s own experience of the pre-specialty era of medical practice.

The eBook is essential reading for all readers interested in the history of cancer treatment and also serves as a historical primer for medical students learning oncology.

Ever since the association between cancer and thrombosis was reported by Jean-Baptiste Bouillaud in the early 19th century, cancer-associated thrombosis has remained a challenging domain of cancer management. Thrombosis can at times be a lead to cancer diagnosis, while it often complicates medical situations as a coexisting disorder. In this handbook, the contributors have compiled comprehensive information on the subject to provide the reader a comprehensive review of current medical literature and guidelines for cancer-associated thrombosis. Key Features -clinically oriented text for application in healthcare settings -current, evidence-based literature reviews and references -includes guidelines on VTE prophylaxis, heparin effects and more -includes information about special cases Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis is an informative handbook for a broad range of readers in medicine, including generalists, residents, and graduate-level trainees.

Thyroid nodules have a high prevalence in populations where iodine deficiency rates are high and in people older than 50 years. Considering that only 5-10% of thyroid nodules are of malignant nature, it is apparent that the clinical issue is the cost-effective differential diagnosis between benign nodules and the malignant ones. This e-book addresses this key issue by giving readers a general overview on the clinical aspect of thyroid nodules and specific details on molecular characterization of the nodules. This e-book is particularly suitable for novice endocrinologists but laboratory biologists and technicians involved in the pre-surgical diagnosis of thyroid cancer can also benefit from the additional technical details offered in this text.

The Topics in Anti-Cancer Research e-Book series covers important advances on both experimental (preclinical) and clinical cancer research in drug development. Major developments in the fields of oncology are covered including mechanisms, tumor and stem cell biology, metastasis, tumor suppressors, cancer drug targets, drug clinical trials, cellular and molecular pathology, genomics and genetics, diagnostics, translational therapeutics, tumor immunology, and cancer prevention and epidemiology. Topics in Anti-Cancer Research is an essential e-book series for oncologists, pharmaceutical scientists, clinicians, and to researchers in other related disciplines.

This is the second volume of the Patent eBook Series titled Topics in Anti-Cancer Research. The eBook includes updated chapters on topics relevant to contemporary cancer research published in the journal, Recent Patents on Anti-Cancer Drug Discovery. This volume covers scientific and patented novel chemotherapeutic agents and drugs for metastatic castration-resistant prostate cancer and Ras/ Raf /MEK/ERK pathway, P1K, AKT and mTORC1/2 inhibitors, ATPase inhibitors for cancer therapy, and sphingomyelin biosynthesis which regulates cancer cell death and growth. Other chapters also explain research on biochemical regulation i.e. cell cycle and energy metabolism, the role of genetic variations of FcγRs gamma receptors in monoclonal antibody based anti-cancer therapy and effectiveness of antiangiogenic therapy, endogenous angiogenesis inhibitors and anti-angiogenic drugs for the treatment of renal cell carcinoma, prevention of cancer by ribonucleotide reductase, anticancer activity of Erlotinib in glioblastoma and the mechanisms of action of nanodrugs and nano-sized camptothecin drugs in cancer chemotherapy. The volume also covers recent studies in the field of onconutrition. The broad range of topics covered in this second volume will be of immense interest to clinicians, scientists and R&D experts seeking new targets for the prevention of cancer, novel oncogenic biomarkers, and methods for cancer therapy.